China SXT Pharmaceuticals, Inc.SXTCEarnings & Financial Report
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
Revenue
$939.6K
Gross Profit
$288.3K
Operating Profit
$-9.3M
Net Profit
$-9.7M
Gross Margin
30.7%
Operating Margin
-995.0%
Net Margin
-1032.0%
YoY Growth
-22.2%
EPS
$-19.34
Financial Flow
China SXT Pharmaceuticals, Inc. Q2 2024 Financial Summary
China SXT Pharmaceuticals, Inc. reported revenue of $939.6K (down 22.2% YoY) for Q2 2024, with a net profit of $-9.7M (down 548.7% YoY) (-1032.0% margin). Cost of goods sold was $651.2K, operating expenses totaled $9.6M.
Key Financial Metrics
| Total Revenue | $939.6K |
|---|---|
| Net Profit | $-9.7M |
| Gross Margin | 30.7% |
| Operating Margin | -995.0% |
| Report Period | Q2 2024 |
China SXT Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
China SXT Pharmaceuticals, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2026 | $829.5K | +0.0% | $-802.6K | -96.8% |
| Q2 2025 | $829.5K | -11.7% | $-802.6K | -96.8% |
| Q2 2024 | $939.6K | -22.2% | $-9.7M | -1032.0% |
| Q2 2023 | $1.2M | +17.6% | $-1.5M | -123.7% |
| Q2 2022 | $1.0M | -73.4% | $-3.1M | -300.9% |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|---|---|
| Revenue | $1.0M | $1.2M | $939583 | $829490 | $829490 |
| YoY Growth | -73.4% | 17.6% | -22.2% | -11.7% | 0.0% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|---|---|
| Assets | $22.7M | $22.2M | $14.6M | $31.0M | $21.7M |
| Liabilities | $8.9M | $7.3M | $9.5M | $16.0M | $6.2M |
| Equity | $13.8M | $14.5M | $5.1M | $15.0M | $15.4M |
Cash Flow
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|---|---|
| Operating CF | $-312349 | $-549125 | $-579568 | $-1.4M | $-1.4M |